<p>Data from end-of-period visit showing median (interquartile range) by dosing regimen in common concentration units. Serum TFV C<sub>pre-dose</sub>, PBMC TFV-DP C<sub>pre-dose</sub>, and cervicovaginal lavage include African clinical sites; other parameters are calculable only for US clinical sites. Rectal sponges are only from one US site. For values below the LLOQ,<[median LLOQ] is shown. Cervicovaginal lavage results were corrected for estimated average 20× dilution of 0.5 mL cervicovaginal fluid in 10 mL lavage fluid <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0055013#pone.0055013-Mitchell1" target="_blank">[11]</a>.</p
BackgroundTenofovir (TFV) gel is being evaluated as a microbicide with pericoital and daily regimens...
<p>(p<0.001, robust RSE<sub>TFV</sub> = 0.67, RSE<sub>TFVdp</sub> = 0.66) Shaded regions are the 1...
BackgroundWe evaluated the association of inflammation and dysbosis on cervicovaginal fluid (CVF) te...
<p>Side-by-side boxplots of end-of-period visit data for all participants by anatomic site and dosin...
(A) ARV drug and TFV-DP levels in vaginal biopsies collected on Day 7 within 30 min of pod-IVR remov...
(A) ARV drug and TFV-DP levels in vaginal biopsies collected on Day 7 within 30 min of pod-IVR remov...
BACKGROUND: Oral and vaginal preparations of tenofovir as pre-exposure prophylaxis (PrEP) for human ...
BACKGROUND: Tenofovir (TFV) gel is being evaluated as a microbicide with pericoital and daily regime...
<p>Each set of figures documents the 30 min drug quantification in the left-side graph and the 24 hr...
<p>Blue, Day 34 (<i>N</i> = 2); red, Day 35 (<i>N</i> = 2); and green, Day 36 (<i>N</i> = 2). The in...
<p>Plasma TFV exposure is correlated linearly with rectal sponge TFV exposure. (p<0.001, robust RSE ...
Background: Tenofovir (TFV) gel is being evaluated as a microbicide with pericoital and daily regime...
<div><h3>Background</h3><p>Oral and vaginal preparations of tenofovir as pre-exposure prophylaxis (P...
Oral and vaginal preparations of tenofovir as pre-exposure prophylaxis (PrEP) for human immunodefici...
Mucosal concentrations of TFV and TFV-DP based on community state type (CST) at end of treatment (vi...
BackgroundTenofovir (TFV) gel is being evaluated as a microbicide with pericoital and daily regimens...
<p>(p<0.001, robust RSE<sub>TFV</sub> = 0.67, RSE<sub>TFVdp</sub> = 0.66) Shaded regions are the 1...
BackgroundWe evaluated the association of inflammation and dysbosis on cervicovaginal fluid (CVF) te...
<p>Side-by-side boxplots of end-of-period visit data for all participants by anatomic site and dosin...
(A) ARV drug and TFV-DP levels in vaginal biopsies collected on Day 7 within 30 min of pod-IVR remov...
(A) ARV drug and TFV-DP levels in vaginal biopsies collected on Day 7 within 30 min of pod-IVR remov...
BACKGROUND: Oral and vaginal preparations of tenofovir as pre-exposure prophylaxis (PrEP) for human ...
BACKGROUND: Tenofovir (TFV) gel is being evaluated as a microbicide with pericoital and daily regime...
<p>Each set of figures documents the 30 min drug quantification in the left-side graph and the 24 hr...
<p>Blue, Day 34 (<i>N</i> = 2); red, Day 35 (<i>N</i> = 2); and green, Day 36 (<i>N</i> = 2). The in...
<p>Plasma TFV exposure is correlated linearly with rectal sponge TFV exposure. (p<0.001, robust RSE ...
Background: Tenofovir (TFV) gel is being evaluated as a microbicide with pericoital and daily regime...
<div><h3>Background</h3><p>Oral and vaginal preparations of tenofovir as pre-exposure prophylaxis (P...
Oral and vaginal preparations of tenofovir as pre-exposure prophylaxis (PrEP) for human immunodefici...
Mucosal concentrations of TFV and TFV-DP based on community state type (CST) at end of treatment (vi...
BackgroundTenofovir (TFV) gel is being evaluated as a microbicide with pericoital and daily regimens...
<p>(p<0.001, robust RSE<sub>TFV</sub> = 0.67, RSE<sub>TFVdp</sub> = 0.66) Shaded regions are the 1...
BackgroundWe evaluated the association of inflammation and dysbosis on cervicovaginal fluid (CVF) te...